Artiva Biotherapeutics (NASDAQ:ARTV) Earns Outperform Rating from Wedbush

Artiva Biotherapeutics (NASDAQ:ARTV)‘s stock had its “outperform” rating reaffirmed by analysts at Wedbush in a research report issued to clients and investors on Tuesday,Benzinga reports. They presently have a $18.00 price objective on the stock. Wedbush’s price objective would suggest a potential upside of 369.36% from the company’s current price.

A number of other research analysts have also commented on ARTV. Needham & Company LLC reiterated a “buy” rating and issued a $23.00 price objective on shares of Artiva Biotherapeutics in a research report on Tuesday. HC Wainwright started coverage on Artiva Biotherapeutics in a research report on Monday, December 30th. They issued a “buy” rating and a $20.00 price objective for the company. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, Artiva Biotherapeutics has a consensus rating of “Buy” and an average target price of $20.40.

Artiva Biotherapeutics Price Performance

Shares of ARTV traded down $0.08 during mid-day trading on Tuesday, hitting $3.84. 23,414 shares of the company traded hands, compared to its average volume of 113,040. The business has a 50-day moving average of $4.97 and a 200 day moving average of $9.43. Artiva Biotherapeutics has a one year low of $3.37 and a one year high of $17.31.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. RA Capital Management L.P. acquired a new position in Artiva Biotherapeutics in the third quarter valued at about $152,234,000. Franklin Resources Inc. acquired a new position in shares of Artiva Biotherapeutics in the 3rd quarter valued at approximately $7,435,000. Geode Capital Management LLC boosted its holdings in shares of Artiva Biotherapeutics by 2.2% in the fourth quarter. Geode Capital Management LLC now owns 315,758 shares of the company’s stock valued at $3,184,000 after buying an additional 6,828 shares during the period. Samsara BioCapital LLC acquired a new position in Artiva Biotherapeutics in the 3rd quarter worth $4,506,000. Finally, Wellington Management Group LLP acquired a new position in shares of Artiva Biotherapeutics during the third quarter worth about $2,912,000.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.